RECRUITING

Neurologic Stem Cell Treatment Study

Talk to us

Conditions

Neurologic DisordersNervous System DiseasesNeurodegenerative DiseasesNeurological DisordersStrokeTraumatic Brain InjuryCadasilChronic Traumatic EncephalopathyCerebral InfarctionCerebral IschemiaCerebral StrokeCerebral HemorrhageParkinsonMulti-System DegenerationMSA - Multiple System AtrophyProgressive Supranuclear PalsyALSAmyotrophic Lateral SclerosisNeuropathyDiabetic NeuropathiesAlzheimer DiseaseDementiaFrontotemporal DementiaLewy Body DiseaseCognitive ImpairmentLewy Body Variant of Alzheimer DiseaseNeurologic DiseaseCerebral Vascular AccidentMultiple SclerosisParkinsons DiseaseDiabetic NeuropathyNeurodegeneration

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/

Official Title

Neurologic Bone Marrow Derived Stem Cell Treatment Study

Quick Facts

Study Start:2016-06
Study Completion:2026-07-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02795052

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care.
  2. 2. Be at least 6 months post-onset of the disease.
  3. 3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment.
  4. 4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.
  5. 5. Be over the age of 18 and capable of providing informed consent.
  6. 6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.
  1. 1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam.
  2. 2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol.
  3. 3. Patients must be capable of providing informed consent.
  4. 4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. .
  5. 5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible.
  6. 6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.

Contacts and Locations

Study Contact

Steven Levy, MD
CONTACT
203-423-9494
stevenlevy@mdstemcells.com

Principal Investigator

Steven Levy, MD
STUDY_CHAIR
MD Stem Cells
Jeffrey Weiss, MD
PRINCIPAL_INVESTIGATOR
Coral Springs

Study Locations (Sites)

MD Stem Cells
Westport, Connecticut, 06880
United States
MD Stem Cells
Coral Springs, Florida, 33065
United States

Collaborators and Investigators

Sponsor: MD Stem Cells

  • Steven Levy, MD, STUDY_CHAIR, MD Stem Cells
  • Jeffrey Weiss, MD, PRINCIPAL_INVESTIGATOR, Coral Springs

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2016-06
Study Completion Date2026-07-31

Study Record Updates

Study Start Date2016-06
Study Completion Date2026-07-31

Terms related to this study

Keywords Provided by Researchers

  • Neurologic Disease
  • Cerebral Vascular Accident
  • Stroke
  • Traumatic Brain Injury
  • Multiple Sclerosis
  • Parkinsons Disease
  • Neuropathy
  • Diabetic Neuropathy
  • Cerebral Ischemia
  • Cognitive Impairment
  • Dementia
  • Neurodegeneration

Additional Relevant MeSH Terms

  • Neurologic Disorders
  • Nervous System Diseases
  • Neurodegenerative Diseases
  • Neurological Disorders
  • Stroke
  • Traumatic Brain Injury
  • Cadasil
  • Chronic Traumatic Encephalopathy
  • Cerebral Infarction
  • Cerebral Ischemia
  • Cerebral Stroke
  • Cerebral Hemorrhage
  • Parkinson
  • Multi-System Degeneration
  • MSA - Multiple System Atrophy
  • Progressive Supranuclear Palsy
  • ALS
  • Amyotrophic Lateral Sclerosis
  • Neuropathy
  • Diabetic Neuropathies
  • Alzheimer Disease
  • Dementia
  • Frontotemporal Dementia
  • Lewy Body Disease
  • Cognitive Impairment
  • Lewy Body Variant of Alzheimer Disease